Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study
BACKGROUND: Rising antimicrobial resistance in Neisseria gonorrhoeae threatens the effectiveness of existing therapies. Ceftriaxone is the only recommended first-line (empiric) treatment for uncomplicated gonorrhea in the United States. Ciprofloxacin is no longer recommended for empiric use because of widespread resistance, but it is inexpensive, taken orally, and effective against susceptible infections, which a resistance test can identify. In the context of rising resistance, resistance-guided treatment (RGT) may reduce treatment failures, complications, and inappropriate use of last-line agents while slowing resistance emergence and preserving the efficacy of new and existing drugs. Understanding where RGT provides economic value-across near-term cost savings, delayed resistance emergence, and avoided antibiotic development costs-can illuminate the broader case for investing in resistance testing and help guide pricing and reimbursement decisions. METHODS AND FINDINGS: We developed an individual-level stochastic simulation model of gonorrhea diagnosis and treatment in the United States, incorporating infection prevalence, symptom status, diagnostic accuracy, resistance profiles, treatment pathways, and partner management (costs in 2025 US dollars[USD]). We evaluated three resistance testing strategies, ciprofloxacin-only, ciprofloxacin + ceftriaxone, and triple-target (including a novel drug A), across a wide range of resistance scenarios. We quantified economic value across three dimensions: (1) per-episode direct medical cost savings, (2) system-level costs attributable to ceftriaxone resistance emergence among men who have sex with men (MSM), and (3) avoided costs of new antibiotic development, estimating the maximum per-test price at which RGT remains cost-neutral. Per-episode cost-neutrality thresholds ranged from near $0 when ceftriaxone resistance was absent to up to $48 per test at 15% prevalence of ceftriaxone resistance (proportion of infections resistant to ceftriaxone). At a prevalence of 50% ciprofloxacin resistance and 5% ceftriaxone resistance, the population-weighted threshold was $7 (95% uncertainty interval [UI] ($3, $11) for a ciprofloxacin-only test and $13 (95% UI [$8-$19]) for a triple-target test. Among MSM, incorporating system-level resistance emergence costs and avoided antibiotic development costs increased the total per-test value to $31 to $114 for a single-target test and $73 to $106 for a triple-target test, depending on whether prescribing practices shift when ceftriaxone resistance reaches 5%. The main limitations are that the model assumes resistance results are available at the same clinical visit to guide initial treatment, does not represent onward transmission or co-resistance between antibiotics, and could estimate longer-term value only for MSM. CONCLUSIONS: Resistance-guided therapy offers economic benefits across multiple dimensions even at relatively high diagnostic prices, supporting investment in gonorrhea resistance testing to improve partner outcomes, delay resistance emergence, and enhance the long-term cost-efficiency of gonorrhea management.
Authors
- Yonatan H. Grad (ORCID: https://orcid.org/0000-0001-5646-1314)
- Betsy Wonderly Trainor (ORCID: https://orcid.org/0009-0006-7768-4940)
- Jeffrey David Klausner (ORCID: https://orcid.org/0000-0002-6922-7364)
- Brooke E Nichols (ORCID: https://orcid.org/0000-0003-4682-4999)
Institutions
- Boston University (US)
- University of Southern California (US)
- Harvard University (US)
- University of Massachusetts Boston (US)
- Office Of Health Economics (GB)
- Amsterdam Institute for Global Health and Development (NL)
- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (US)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1371/journal.pmed.1005073
- Primary Topic
- Reproductive tract infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Administration for Strategic Preparedness and Response
- U.S. Department of Health and Human Services
- Bill and Melinda Gates Foundation
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Wellcome Trust
- Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator
- Department of Health and Social Care
- European Commission
- Ministry of Health, Labour and Welfare
- Novo Nordisk
- Novo Nordisk Fonden
- KfW Entwicklungsbank
- Biomedical Advanced Research and Development Authority